enGene Holdings Inc. (ENGN)

NASDAQ: ENGN · Real-Time Price · USD
3.310
-0.370 (-10.05%)
At close: Jul 11, 2025, 4:00 PM
3.440
+0.130 (3.93%)
After-hours: Jul 11, 2025, 5:13 PM EDT
-10.05%
Market Cap 169.16M
Revenue (ttm) n/a
Net Income (ttm) -79.88M
Shares Out 51.11M
EPS (ttm) -1.68
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 64,774
Open 3.620
Previous Close 3.680
Day's Range 3.260 - 3.660
52-Week Range 2.650 - 11.000
Beta -0.41
Analysts Buy
Price Target 23.29 (+607.9%)
Earnings Date Sep 9, 2025

About ENGN

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a non-viral monotherapy to treat non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) in patients that have been unresponsive to treatment with Bacillus Calmette-Guérin (BCG). enGene Holdings Inc. is based in Montreal, Canada. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 57
Stock Exchange NASDAQ
Ticker Symbol ENGN
Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to 7 analysts, the average rating for ENGN stock is "Buy." The 12-month stock price target is $23.29, which is an increase of 607.90% from the latest price.

Price Target
$23.29
(607.90% upside)
Analyst Consensus: Buy
Stock Forecasts

News

enGene Announces Board and Leadership Appointments to Support Commercial Readiness

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral gene-based immunotherapy company, today announced the appointment of t...

3 days ago - Business Wire

FDA Grants RMAT Designation for enGene's Detalimogene, Enabling Potential for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, or “enGene” or the “Company”), a clinical-stage, non-viral gene-based immunotherapy company, today announced that the U.S. Food ...

16 days ago - Business Wire

enGene Holdings: Looking For An End To The 2025 Decline (Downgrade)

enGene Holdings Inc.'s lead asset, detalimogene voraplasmid, continues to show early promise in non-muscle invasive bladder cancer, with pivotal LEGEND trial data expected in late 2025. Financially, E...

23 days ago - Seeking Alpha

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today reported the grant of inducement equity...

24 days ago - Business Wire

enGene Reports Second Quarter 2025 Financial Results and Provides Business Update

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced its financial results for ...

4 weeks ago - Business Wire

enGene Announces the Resignation of its Chief Medical Officer

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, announced today that Dr. Raj Pruthi resigne...

5 weeks ago - Business Wire

enGene to Present at the Jefferies Global Healthcare Conference

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that Ron Cooper, Chief Exec...

6 weeks ago - Business Wire

enGene Names Amy Pott as Chief Global Commercialization Officer

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced the appointment of Amy Pott...

6 weeks ago - Business Wire

enGene to Participate in Upcoming Investor Conferences

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that management will presen...

2 months ago - Business Wire

enGene to Present at the Stifel 2025 Virtual Targeted Oncology Forum

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that Ron Cooper, Chief Exec...

3 months ago - Business Wire

enGene Reports First Quarter 2025 Financial Results and Provides Business Update

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced its financial results for ...

4 months ago - Business Wire

enGene to Participate in the Leerink Partners Global Healthcare Conference

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that Ron Cooper, Chief Exec...

4 months ago - Business Wire

enGene Holdings Inc.: Unknown Company Which Looks Like A Catch

enGene's DDX platform delivers genetic cargo to mucosal tissues, showing potential to transform genetic medicine beyond rare diseases, with promising preclinical and clinical data. Detalimogene vorapl...

4 months ago - Seeking Alpha

enGene to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimoge...

5 months ago - Business Wire

enGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC)

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimog...

5 months ago - Business Wire

enGene Reports Full Year 2024 Financial Results and Provides a Business Update

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimog...

7 months ago - Business Wire

enGene Holdings: Compelling Early Data Bode Well For Their Near-Term Outlook

enGene is working toward an approval similar to what IBRX got with Anktiva, although without needing BCG co-administration. NMIBC remains an area of unmet need, although it may not be SO unmet that th...

7 months ago - Seeking Alpha

enGene to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimoge...

8 months ago - Business Wire

enGene Announces $60 Million Private Placement Financing

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimoge...

9 months ago - Business Wire

enGene Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene...

9 months ago - Business Wire

enGene Appoints Joan Connolly as Chief Technology Officer and Anthony Cheung, Ph.D., as Chief Scientific Officer

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimoge...

9 months ago - Business Wire

Detalimogene Demonstrates 71% Complete Response Rate at Any Time in Preliminary Analysis of LEGEND Pivotal Cohort

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), is a clinical-stage genetic medicines company whose non-viral lead investigational product detalim...

10 months ago - Business Wire

enGene Reports Third Quarter 2024 Financial Results and Provides a Business Update

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimog...

10 months ago - Business Wire

enGene Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral, intravesical lead product candidate, EG-...

1 year ago - Business Wire

enGene Announces Appointment of Ron Cooper as Chief Executive Officer

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral, intravesical lead product candidate, EG-...

1 year ago - Business Wire